Fondazione Italiana Linfomi - ETS
Quick facts
Marketed products
- R-CVP · Other
- Treatment plan · Oncology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Phase 3 pipeline
- Ciclofosfamide · Other
- Doxorubicina · Other
- Ibritumomab Tiuxetan + Maintenance · Oncology
Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that targets CD20 on B cells and delivers cytotoxic radiation directly to lymphoma cells. - Maintenance weekly x4 · Oncology
This drug targets the CD19 protein on B cells to induce apoptosis. - R-CHOP or R-bendamustine · Oncology
R-CHOP and R-bendamustine are combination chemotherapy regimens that use rituximab (an anti-CD20 monoclonal antibody) combined with cytotoxic chemotherapy agents to kill B-cell lymphomas. - R-FM · Oncology
R-FM is a rituximab-based chemoimmunotherapy regimen combining rituximab with fludarabine and mitoxantrone for B-cell lymphomas. - R-MANT · Oncology
R-MANT is a rituximab-based immunochemotherapy regimen combining rituximab with chemotherapy agents for treatment of lymphoid malignancies. - R2-MANT · Oncology
R2-MANT is a mantle cell lymphoma-directed immunotherapy combining rituximab with a novel antitumor mechanism in phase 3 development. - RCHOP o R-miniCHOP at standard doses · Oncology
R-CHOP and R-miniCHOP combine chemotherapy and a monoclonal antibody targeting CD20 on B cells. - Standard Maintenance · Oncology
Standard Maintenance refers to a continuation therapy regimen rather than a specific drug with a defined molecular mechanism. - Vincristina · Other
Phase 2 pipeline
- ABVD and Radiotherapy · Oncology
Brentuximab vedotin targets CD30 - Bendamustine, Lenalidomide, Rituximab · Oncology
Bendamustine is a chemotherapy medication that works by interfering with DNA replication, Lenalidomide is an immunomodulatory drug that affects the immune system, Rituximab is a monoclonal antibody that targets CD20 on B cells. - Bortezomib-Rituximab-Bendamustine · Oncology
Bortezomib-Rituximab-Bendamustine is a combination of a proteasome inhibitor, a monoclonal antibody, and a chemotherapy agent. - BR-DHAP
- dose dense ABVD
- Lenalidomide and Dexametasone
- LR-CHOP21
- Mosunetuzumab in combination with Zanubrutinib
- R-CHOP with doxorubicin · Oncology
Rituximab targets CD20 on B cells, doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - Rituximab-Dexamethasone-Lenalidomide
- Rituximab, Mitoxantrone, Bendamustine
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Fondazione Italiana Linfomi - ETS portfolio CI brief
- Fondazione Italiana Linfomi - ETS pipeline updates RSS
Frequently asked questions about Fondazione Italiana Linfomi - ETS
What are Fondazione Italiana Linfomi - ETS's marketed drugs?
Top marketed products include R-CVP, Treatment plan.
What is Fondazione Italiana Linfomi - ETS's pipeline?
Fondazione Italiana Linfomi - ETS has 11 drugs in Phase 3, 11 in Phase 2, 0 in Phase 1. Late-stage candidates include Ciclofosfamide, Doxorubicina, Ibritumomab Tiuxetan + Maintenance, Maintenance weekly x4.
Related
- R-CVP · Other
- Treatment plan · Oncology
- Sector hub: All tracked pharma companies